Posted on 26/04/2010 in Medical Company Financials Bard has published its financial report for the first quarter of 2010, during which the company's sales saw an increase of nine per cent compared to the same period of 2009.
The medical technology firm's three-month net sales figure came to $650.8 million (420.8 million pounds), with takings from its vascular, urology, oncology and surgical specialties divisions all seeing year-on-year improvements.
It was also able to achieve growth in terms of constant currency revenue and adjusted earnings per share that were in line with its guidance.
Timothy Ring, chairman and chief executive officer of Bard, stated that the company will now look to continue making investments over the course of 2010 that will cement its position in the market.
He said: "While we have not seen any meaningful change in hospital market trends, our product portfolio continues to benefit from our research and development and business development activities."
Earlier this year, the company published trial results from a study of its Flair Endovascular Stent Graft, demonstrating the device's effectiveness among haemodialysis patients.Other news stories from 26/04/2010
Read more in the Zenopa News Archive
How this news is generated
|
